European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 3 , Pages 366-370, September 2008

Efficacy of Polidocanol Foam versus Liquid in Sclerotherapy of the Great Saphenous Vein: A Multicentre Randomised Controlled Trial with a 2-year Follow-up

  • P. Ouvry

      Affiliations

    • Cabinet d'angiologie, 9 rue Jules Ferry, Dieppe, France
  • ,
  • F.-A. Allaert

      Affiliations

    • Department of Epidemiology, Biostatistics and Occupational Medicine, Mc Gill University, Montreal, Canada
  • ,
  • P. Desnos

      Affiliations

    • Cabinet de Médecine Vasculaire, 2 avenue Bagatelle, Caen, France
  • ,
  • C. Hamel-Desnos

      Affiliations

    • Centre Hospitalier Privé Saint Martin, 18 rue des Roquemonts, 14050 Caen, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 231 433434; fax: +33 231 433330.

Received 28 November 2007; accepted 13 April 2008. published online 04 June 2008.

Abstract 

Objective

To compare the relative efficacy of polidocanol (Aetoxisclerol®, Kreussler, Germany) when used as a foam or liquid in the treatment of saphenous incompetence.

Materials and methods

Multicentre, prospective, randomised controlled trial conducted in patients with incompetence of the great saphenous vein (GSV) with a truncal diameter of 4–8mm. The great saphenous vein was injected using a single injection 2–2.5ml of either 3% polidocanol or sclerosant foam containing one-fifth 3% polidocanol to four-fifths air (DSS technique). Clinical assessments and duplex ultrasound scanning were performed after 3 weeks and then every 6 months for 2 years. No re-injection was performed irrespective of the immediate result. The main outcome measure was elimination of GSV reflux.

Results

Ninety-five patients participated in the study, 47 were randomised to the foam sclerosant group and 48 to the liquid group. No significant difference between the 2 groups was found regarding sex, age, height, weight and saphenous vein diameter. At 3 weeks, complete elimination of reflux was obtained in 17 of the 48 patients (35%) who received liquid sclerotherapy, versus 40 of the 47 subjects (85%) in the foam group (p<0.001, Chi squared). The incidence of immediate venous spasm and the length of the sclerotic reaction, occlusion measured by echography, were significantly greater in the foam group. There was no difference in the incidence of ecchymosis, inflammatory reactions or other side effects. Follow-up of 6, 12, 18 and 24 months confirms our early results published in 2003. In total only 5 patients were lost to follow-up at 2 years (all of them were in foam group). These patients were included in the final outcome analysis as treatment failures (success rates at 2 years: 53% in foam group and 12% in liquid group).

Conclusion

The sclerosant foam used in this study was more than twice as effective as the liquid from which the foam was prepared.

Keywords: Varicose veins, Foam sclerotherapy, Polidocanol, Ultrasound guided sclerotherapy, Sclerotherapy

 

PII: S1078-5884(08)00225-6

doi:10.1016/j.ejvs.2008.04.010

European Journal of Vascular & Endovascular Surgery
Volume 36, Issue 3 , Pages 366-370, September 2008